Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLR 131 in Pediatric Relapsed or Refractory High-Grade Glioma
NCT05610891Phase 1Active, not recruiting
- Sponsor
- Cellectar Biosciences
- Start
- Oct 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 1, open-label trial of Iopofosine I-131 in glioma (2 cohorts), sponsored by Cellectar Biosciences. Primary endpoints: Safety Evaluation of CLR 131 and Progression Free Survival. Started Oct 2023; status: active, not recruiting.
02
Drugs
Iopofosine I-131
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05610891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610891.